Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Lilly Pulitzer is serving up a Valentine's Day partnership with Lele Sadoughi, the New York-based accessories brand. Marking their second collaboration, "Lilly Loves Lele" is a six-piece limited ...

Eli Lilly ( LLY 3.89%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...

Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory problems with its new blockbuster obesity and diabetes drugs that weighed on ...

The latest declines in Eli Lilly's stock price occurred in response to management's presentation at the annual JPMorgan Healthcare conference. On Jan. 14, CEO David Ricks told investors that 2024 ...

The annual Alexandria Boutique Warehouse Sale is coming back to Old Town for its 21st year next month. On Saturday, February 1, and Sunday, February 2, shoppers can expect to find deep discounts on ...

In the first half of 2024, it seemed Eli Lilly (NYSE ... presentation at the annual JPMorgan Healthcare conference. On Jan. 14, CEO David Ricks told investors that 2024 sales would come in ...

Jan 14 (Reuters) - Eli Lilly's (LLY.N), opens new tab stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the ...

Last July, Lilly's Alzheimer's disease candidate Kisunla earned approval from the FDA to treat Alzheimer's disease. Intended for early-stage patients with mild cognitive impairment, annual sales ...

Eli Lilly (LLY) shares tumbled Tuesday after the drugmaker lowered its revenue forecast for the 2024 fiscal year. The maker of weight-loss drugs Mounjaro and Zepbound said sales of the drugs grew ...

Lilly's stock went on a tear in the beginning of 2023, with the company's shares doubling as investors bet on the drug's popularity. The stock stumbled in October last year, after Zepbound's sales ...

Eli Lilly shares climbed 32% last year but have slumped more than 16% since October after the company reported third quarter sales of the two drugs below Wall Street’s expectations, prompting ...